ARTICLE | Distillery Therapeutics
A large-HBsAg vaccine for hepatitis B
November 8, 2022 5:06 PM UTC
A nanoparticle vaccine displaying yeast-derived large (L)-HBsAg — which contains a receptor-binding domain within its preS1 region that is essential for viral particle formation — could prevent infection by more HPV strains than commercially available vaccines comprising small (S)-HBsAg. The vaccine was developed by embedding L-HBsAg in a unilamellar liposome nanoparticle, and combined with a squalene-based adjuvant...
BCIQ Target Profiles